Table 2.
Baseline characteristics of the included studies
| Study ID | Sample size, n | Age (years) | Male, n(%) | Onset to treatment time, (min) | Baseline NIHSS, mean (SD) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | |
| Bivard et al. 2022 [19] | n = 55 | n = 49 | 73.33 ± 18.27 | 71.33 ± 14.51 | 33 (60%) | 30 (61%) | 107.33 ± 67.75 | 96.33 ± 49.64 | 9 ± 6.85 | 10 ± 9.16 |
| Campbell et al. 2018 [35] | n = 101 | n = 101 | 70.4 ± 15.1 | 71.9 ± 13.7 | 58 (57%) | 52 (51%) | 127.6 ± 40.61 | 138 ± 54.15 | 17 ± 7.52 | 17 ± 7.52 |
| Haley et al. 2010 [36] |
TNK 0.1: n = 31 TNK 0.25: n = 31 TNK 0.4: n = 19 |
n = 31 |
TNK 0.1: 67 ± 19 TNK 0.25: 69 ± 15 TNK 0.4: 68 ± 16 |
72 ± 16 |
TNK 0.1: 12 (39%) TNK 0.25: 16 (52%) TNK 0.4: 13 (68%) |
17 (51%) | NA | NA |
TNK 0.1: 8 ± 4.66 TNK 0.25: 10.33 ± 7 TNK 0.4: 10.33 ± 9.6 |
11.6 ± 9.32 |
| Huang et al. 2015 [34] | n = 47 | n = 49 | 71 ± 13 | 71 ± 12 | 30 (64%) | 31 (63%) | 184 ± 44 | 192 ± 45 | 13 ± 6.88 | 11.6 ± 6.11 |
| Kvistad et al. 2022 [21] | n = 100 | n = 104 | 73·2 ± 12·6 | 68·6 ± 15·6 | 45 (45%) | 53 (51%) | 103.16 ± 51.90 | 105 ± 52.62 | 13.4 ± 6.6 | 13.2 ± 6.4 |
| Li et al. 2021 [23] |
TNK 0.1: n = 60 TNK 0.25: n = 57 TNK 0.32: n = 60 |
n = 59 |
TNK 0.1: 62.4 ± 11.1 TNK 0.25: 64.3 ± 12.8 TNK 0.32: 64.8 ± 12.1 |
66.5 ± 12.6 |
TNK 0.1: 48 (80%) TNK 0.25: 42 (73.7%) TNK 0.32: 42 (70%) |
38 (64.4%) |
TNK 0.1: 135 ± 105.6 TNK 0.25: 136 ± 75.3 TNK 0.32:145.33 ± 114.7 |
119.3 ± 128.42 |
TNK 0.1: 7.33 ± 3.80 TNK 0.25: 8.33 ± 5.33 TNK 0.32: 8.5 ± 4.6 |
8.33 ± 5.32 |
| Logallo et al. 2017 [37] | n = 549 | n = 551 | 70.8 ± 14.4 | 71.2 ± 13.2 | 321 (58%) | 339 (62%) | 125.67 ± 75 | 121.6 ± 69.87 | 5.6 ± 5.4 | 5.8 ± 5.2 |
| Menon et al. 2022 [22] | n = 806 | n = 771 | 73.33 ± 14.85 | 72.67 ± 15.6 | 424 (52.6%) | 398 (51.6%) | 135 (69.05%) | 138 ± 69.1 | 10.33 ± 7.43 | 11 ± 8.14 |
| Parsons et al. 2012 [38] |
TNK 0.1: n = 25 TNK 0.25: n = 25 |
n = 25 |
TNK 0.1: 72 ± 6.9 TNK 0.25: 68 ± 9.4 |
70 ± 8.4 |
TNK 0.1: 13 (52%) TNK 0.25: 13 (52%) |
12 (48%) |
TNK 0.1: 3.1 ± 0.9 (h) TNK 0.25: 3.0 ± 0.7 (h) |
2.7 ± 0.8 (h) |
TNK 0.1: 14.5 ± 2.3 TNK 0.25: 14.6 ± 2.3 |
14 ± 2.3 |
| Study ID | Comorbidities, n(%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AF | HTN | DM | Dyslipidaemia | Smoking | ||||||
| Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | Tenecteplase | Alteplase | |
| Bivard et al. 2022 [19] | 8 (15%) | 7 (15%) | 30 (55%) | 31 (63%) | 11 (30%) | 17 (35%) | 21 (38%) | 22 (45%) | 8 (15%) | 9 (18%) |
| Campbell et al. 2018 [35] | 27 (27%) | 40 (40%) | 64 (63%) | 63 (62%) | 10 (10%) | 18 (18%) | N/A | N/A | 18 (18%) | 11 (11%) |
| Haley et al. 2010 [36] | NA | NA |
TNK 0.1: 25 (81%) TNK 0.25: 25 (81%) TNK 0.4: 17 (90%) |
22 (71%) |
TNK 0.1: 6 (19%) TNK 0.25: 7 (23%) TNK 0.4: 4 (21%) |
4 (13%) |
TNK 0.1: 16 (52%) TNK 0.25: 15 (48%) TNK 0.4: 8 (42%) |
17 (55%) |
TNK 0.1: 2 (6.5%) TNK 0.25: 7 (23%) TNK 0.4: 0 (0%) |
7 (23%) |
| Huang et al. 2015 [34] | 19 (40%) | 15 (31%) | 20 (43%) | 28 (57%) | 7 (15%) | 7 (14%) | 4 (9%) | 7 (14%) | 13 (28%) | 10 (20%) |
| Kvistad et al. 2022 [21] | 9 (9%) | 8 (8%) | 56 (56%) | 48 (46%) | 17 (17%) | 11 (11%) | 30 (30%) | 33 (32%) | 24 (24%) | 25 (24%) |
| Li et al. 2021 [23] |
TNK 0.1: 8 (13.3%) TNK 0.25: 4 (7.0%) TNK 0.32: 14 (23.3%) |
6 (10.2%) |
TNK 0.1: 43 (71.7%) TNK 0.25: 37 (64.9%) TNK 0.32: 35 (58.3%) |
42 (71.2%) |
TNK 0.1: 14 (23.3%) TNK 0.25: 9 (15.8%) TNK 0.32: 15 (25%) |
11 (18.6%) |
TNK 0.1: 17 (28.3%) TNK 0.25: 13 (22.8%) TNK 0.32: 10 (16.7%) |
11 (18.6%) |
TNK 0.1: 25 (41.7%) TNK 0.25: 25 (43.9%) TNK 0.32: 21 (35%) |
24 (40.7%) |
| Logallo et al. 2017 [37] | 50 (9%) | 69 (13%) | 246 (45%) | 236 (43%) | 72 (13%) | 74 (13%) | 61 (11%) | 65 (12%) | 169 (31%) | 177 (32%) |
| Menon et al. 2022 [22] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Parsons et al. 2012 [38] |
TNK 0.1: 9 (36%) TNK 0.25: 13 (52%) |
6 (24%) |
TNK 0.1: 16 (64%) TNK 0.25: 16 (64%) |
15 (60)% |
TNK 0.1: 8 (32%) TNK 0.25: 6 (24%) |
1 (4%) |
TNK 0.1: 13 (52%) TNK 0.25: 15 (60%) |
9 (36%) |
TNK 0.1: 9 (36%) TNK 0.25: 5 (20%) |
1 (4%) |
NIHSS national institute of health stroke scale, AF atrial fibrillation, HTN hypertension, DM diabetes mellitus, NA not available, n number, SD standard deviation